Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hikma lifts dividend after double-digit growth in 2023

(Sharecast News) - Hikma Pharmaceuticals impressed the market with its annual results on Thursday as it bumped up its dividend by almost a third following double-digit growth in core revenues and profits in 2023. Full-year revenues totalled $2.88bn, up 14% on 2022, with growth seen across its three main businesses: Injectables, Branded and Generics.

Injectables, which account for 42% of sales, increased revenues by 6%; Branded revenues, which make up a quarter of the business, rose by 3%; but Generics sales jumped 39% which Hikma put down to a good recovery in the base business and a strong contribution from the authorised generic of sodium oxybate, which was launched at the start of 2023.

Core operating profits were up 19% year-on-year at $707m, helped by rising margins and improving profitability in Branded and Generics. Reported operating profit was up 30%, but that reflected higher impairment charges in 2022.

The company raised its final dividend to 47 cents, from 37 cents previously, bringing the total dividend for 2023 to 72 cents, up 29% on 2022.

"Hikma delivered strong growth and made significant progress in 2023," said chief executive Riad Mishlawi, who was appointed as leader in September. "Our results demonstrate momentum across each of our three businesses, with new product launches and partnerships continuing to expand our portfolio, including into more complex areas such as oncology."

Looking ahead, Hikma guided to revenue growth to slow to between 4% and 6% in 2024, with core operating profits in the range of $660m to $700m.

Nevertheless, the share price was up 5.2% at 2,102p by 0838 GMT.

Share this article

Related Sharecast Articles

R&Q Insurance shares plummet on weak guidance
(Sharecast News) - R&Q Insurance, the AIM-listed non-life insurer, lost almost half of its market value on Friday after announcing it would report a "significant pre-tax loss" for last year.
SigmaRoc delivers 'solid' Q1 performance
(Sharecast News) - Limestone group SigmaRoc said on Friday that it had delivered a "solid Q1 performance", with underlying earnings in line with management expectations.
Samsung in line to secure $6bn in US government grants
(Sharecast News) - Electronics giant Samsung will unveil a $44.0bn White House programme aimed at bringing semiconductor production back to America as soon as next week, with the memory chip maker in line to secure up to $6.0bn in government grants.
BAE Systems 'still riding high', says Deutsche Bank
(Sharecast News) - Deutsche Bank has hiked its target price for BAE Systems and maintained a 'buy' rating on the aerospace and defence stock, saying that recent growth momentum is likely to continue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.